Physician profile
Alexandra Taylor
NPI 1700571759
$3,273.52
in general payments reported to CMS, 2019-2025
19 companies · $3,068 in 2025
The $3,068 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $205 · 2025: $3,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,017 · Education: $194 · Travel and Lodging: $62.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,017.03 |
| Education | $193.99 |
| Travel and Lodging | $62.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $593.80 | 2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $564.18 | 2025 | |
| Novartis Pharmaceuticals Corporation | $363.92 | 2025 | |
| Abbvie INC. | $338.88 | 2025 | |
| Pfizer INC. | $269.02 | 2025 | |
| Genzyme Corporation | $205.12 | 2024-2025 | |
| Janssen Biotech, INC. | $163.78 | 2025 | Tremfya |
| Blueprint Medicines Corporation | $128.76 | 2025 | Ayvakit |
| Janssen Scientific Affairs, LLC | $112.50 | 2025 | Tremfya |
| Organon LLC | $107.00 | 2025 | Vtama |
| Lilly USA, LLC | $99.00 | 2024 | |
| Arcutis Biotherapeutics, INC. | $83.46 | 2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $75.37 | 2025 | Sotyktu |
| Regeneron Pharmaceuticals, INC. | $49.57 | 2025 | Dupixent |
| Regeneron Healthcare Solutions, INC. | $44.95 | 2025 | Dupixent, Libtayo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $21.57 | 2025 | Opzelura |
| Kyowa Kirin, INC. | $18.88 | 2025 | |
| Organogenesis INC. | $17.64 | 2025 | Puraply Wound Matrix |
| Amgen INC. | $16.12 | 2024 | Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.